Researchers have long known that patients who leave emergency departments before medically advised use more emergency care services, are more likely to be readmitted to the hospital and face higher ...

Increased use of ventilation and air cleaners, designed to mitigate the spread of viral infections in hospitals, is likely to have unpredictable effects and may cause viral particles to move around ...

The Cybersecurity and Infrastructure Security Agency and Food and Drug Administration Jan. 30 released notices warning of ...

Dexamethasone reduced mortality among patients hospitalized with COVID-19, especially those who were also receiving respiratory support.

Paxlovid may offer marginal benefits for low-risk children with COVID-19; however, among high-risk children with COVID-19, Paxlovid is a safe oral option.

Researchers have long known that patients who leave emergency departments before medically advised use more emergency care ...

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Paxlovid vs placebo reduced COVID-19-related hospitalization and death due to any cause through 28 days, as well as the duration of COVID-19 symptoms.

Along with claiming the lives of 1.2 million Americans, the COVID-19 pandemic has been described as a mass disabling event.

Despite long COVID’s vast reach, and more than $1 billion spent on research, no new treatments have been brought to market.

Friday marked five years since a suburban hospital announced it was treating the first confirmed COVID-19 patient in Illinois ...

Innovative Device Provides Clear Vision, Maintains Continuous Oxygen Delivery, and Clears Aspirate and Debris During ...